In the post–Roe v. Wade United States, scientists are on the cusp of a watershed moment in birth control, the introduction of new, viable male contraceptives. As we watch brave individuals fight to make medical history, Big Pharma’s reluctance to invest in these new products remains a maddening obstacle to the groundbreaking prospect of changing family planning and gender politics forever.
